For instance, drugs targeting inhibitory kappa B kinases (IKKs), which are required for NF-κB activation, have been developed; however, these drugs are not specific inhibitors of NF-κB transcriptional activity and also have many off-target effects.16 Therefore, characterizing the individual role of key NF-κB subunits in cancer may help to overcome these obstacles. The gene discussed is NFKB1; the disease is cancer.